Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD.

@article{Khadzhynov2011PlasmaPO,
  title={Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD.},
  author={Dmytro Khadzhynov and Torsten Slowinski and Ina Lieker and Claudia D. Spies and Birgit Puhlmann and T K{\"o}nig and Alexander Uhrig and Karen E. Eggers and H H Neumayer and F Traunm{\"u}ller and Christian Joukhadar and Harm Peters},
  journal={International journal of clinical pharmacology and therapeutics},
  year={2011},
  volume={49 11},
  pages={
          656-65
        }
}
BACKGROUND Daptomycin is a novel antibiotic with primarily renal elimination. METHODS In an open-label, prospective trial, the pharmacokinetics of daptomycin after single (8 mg/kg BW) and multiple intravenous doses (4 mg/kg BW) at steady state were determined in critically ill, dialysis-dependent patients treated with continuous veno-venous hemodialysis (CVVHD). Daptomycin levels were determined by HPLC. Subjects with normal renal function received one dose of 4 mg/kg BW of daptomycin… 
Pharmacokinetics of Daily Daptomycin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
TLDR
The quantification of trough concentrations (Cmin) appears to be a good surrogate to estimate AUC24h and to monitor daptomycin treatment in patients undergoing CRRT.
Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy
TLDR
Q24 h dosing of daptomycin up to 12 mg kg−1 provides comparable drug exposure in patients on CVVHD and in those with CrCl ≥ 30 ml min−1, with optimal exposure for efficacy.
Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy.
TLDR
The model predicted that the combination of 6 mg/kg q24h daptomycin dose and CRRT dose of 30-35 mL/h/kg would achieve the best balance of efficacy and safety.
Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy
TLDR
In critically ill patients undergoing CRRT, daptomycin exposure with once-daily dosing was similar to ICU patients with normal renal function, but lower compared to healthy volunteers.
Population pharmacokinetics of daptomycin in critically ill patients.
Therapeutic Drug Monitoring of Daptomycin: A Retrospective Monocentric Analysis
TLDR
Daptomycin plasma concentrations are often unpredictable as shown by highly variable drug exposure that is only partially explained by dose administered and underlying renal function.
Clinical Pharmacokinetics of Daptomycin
TLDR
The pharmacokinetics of daptomycin are altered under certain pathophysiological conditions, resulting in high interindividual variability, and may be of interest for certain patients, such as intensive care unit patients, patients with renal or hepatic insufficiency, dialysis patients, obese patients, or children.
Optimizing Antimicrobial Dosing for Critically Ill Patients with MRSA Infections: A New Paradigm for Improving Efficacy during Continuous Renal Replacement Therapy
The dosage regimen of vancomycin, teicoplanin and daptomycin remains controversial for critically ill patients undergoing continuous renal replacement therapy (CRRT). Monte Carlo simulation was
Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin® Outcomes Registry and Experience
TLDR
High-dose daptomycin at doses >6 mg/kg/day was effective and well tolerated and is a potential therapeutic option in patients with difficult-to-treat Gram-positive infections.
...
1
2
3
...